This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): latanoprost
Description: Xalatan (Latanoprost) is a prostaglandin F2alpha analog. Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Deal Structure: In March 2009, Pfizer and Bausch & Lomb announced a co-promotion agreement involving both companies' prescription ophthalmic pharmaceuticals in the United States. The five-year agreement includes Pfizer's Xalatan (latanoprost ophthalmic solution) and Bausch & Lomb's Alrex (loteprednol etabonate ophthalmic suspension 0.2%), Lotemax (loteprednol etabonate ophthalmic suspension 0.5%) and Zylet (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension). The co-promotion agreement also will apply to Bausch & Lomb's besifloxacin ophthalmic suspension 0.6%.
Under the terms of the agreement, both the Pfizer and Bausch & Lomb sales forces will promote Xalatan, Alrex, Lotemax, Zylet and besifloxacin (subject to FDA approval). Financial terms of the agreement were not disclosed.
Bausch + Lomb and Valeant
In May 2013, Valeant and Bausch + Lomb announced that they have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for...See full deal structure in Biomedtracker
Partners: Valeant Pharmaceuticals International, Inc.
Pink Sheet Xalatan Patent Ruling
Pink Sheet In Brief: Pharmacia & Upjohn's Xalatan
Pink Sheet Pharmacia Xalatan first-line use
Additional information available to subscribers only: